The package insert for propranolol is inadequate as the sole source of drug information, as it fails to list several evidence-based uses such as hypertension and angina pectoris.
Answers are grounded in this paper and cite their sources.
Package inserts may omit evidence-based indications for propranolol; this leaves open questions on optimal clinician information sources.
In the 5 years since propranolol was introduced in the United States, the indications for its use stated in the package insert have remained virtually unchanged. During this period no studies have appeared that rigorously establish the relative role of propranolol for these indications by comparing it with other forms of therapy. In addition, at least 34 other uses for propranolol therapy have been reported; of these, there is substantial evidence for efficacy only in the management of hypertension, angina pectoris, and thyrotoxicosis. The package insert does not list these new uses or other "uses" for propranolol that have appeared in the medical literature. The physician in practice may experiment with an approved drug for an unapproved use, but the patient should give informed consent to the experiment, and the experiment should be reported to the FDA. The current package insert for propranolol is not adequate as the sole source of drug information for optimal drug selection.
No takes yet. Share an insight, caveat, or question.
Howard F. Morrelli (1973) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: